/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Mereo Biopharma Group PLC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.98 0.12(12%) MREO at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 1.745
Highest Today 2.175
Today’s Open 1.775
Prev. Close 1.75
52 Week High 3.94
52 Week Low 1.47
Day’s Range: Low 1.745 High 2.175
52-Week Range: Low 1.47 High 3.94
1 day return -
1 Week return +4.55
1 month return +9.24
3 month return +12.06
6 month return -23.52
1 year return -45.14
3 year return +134.26
5 year return -8.87
10 year return -

Institutional Holdings

HHG PLC 11.12

Rubric Capital Management LP 9.62

Mangrove Partners 5.43

Deerfield Management Co 4.22

Alkeon Capital Management, LLC 2.95

Rock Springs Capital Management LP 2.81

683 Capital Management LLC 2.73

Clearline Capital LP 2.27

Goldman Sachs Group Inc 1.94

Aberdeen Group PLC 1.90

abrdn World Healthcare 1.82

Tejara Capital Ltd 1.53

abrdn Life Sciences Investors 1.31

UBS (Lux) EF Biotech (USD) P-acc 1.07

Renaissance Technologies Corp 0.93

FMR Inc 0.93

Fidelity Select Health Care 0.92

Schonfeld Strategic Advisors LLC 0.57

Fidelity Select Biotechnology 0.54

Morgan Stanley - Brokerage Accounts 0.49

Marshall Wace Asset Management Ltd 0.48

Atle Fund Management AB 0.48

Citadel Advisors Llc 0.48

Fidelity Advisor Biotechnology I 0.48

Fidelity Advisor Health Care I 0.47

Two Sigma Investments LLC 0.41

Soleus Capital Management, L.P. 0.38

HealthInvest Sustainable Healthcare E 0.34

iShares Genomics Immnlgy & Hlthcr ETF 0.23

Healthlnvest S&M Cap Healthcare C 0.14

Fidelity VIP Health Care Initial 0.13

UBS Global Equity Biotech 0.08

SPDR® S&P® International Small Cap ETF 0.07

Fidelity Nasdaq Composite Index 0.06

Arctic Aurora LifeScience I 0.03

Virtus LifeSci Biotech Clinical Trls ETF 0.03

Avanza Healthcare by Samuelsson & Hult 0.02

ActivePassive International Equity ETF 0.02

Forefront Tiresias Strategy 0.01

iShares Genomics Imnlgy & Hlthcr ETF CAD 0.01

Market Status

Strong Buy: 6

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 278.48 M

PB Ratio 6.2324

PE Ratio 0.0

Enterprise Value 242.11 M

Total Assets 76.39 M

Volume 11642082

Company Financials

Annual Revenue FY23:10000000 10.0M, FY22:1507000 1.5M, FY21:36464000 36.5M, FY20:393000 0.4M, FY19:-122000 -0.1M

Annual Profit FY23:7426000 7.4M, FY22:2443000 2.4M, FY21:18556000 18.6M, FY20:-15954000 -16.0M, FY19:-23730000 -23.7M

Annual Net worth FY23:-29466000 -29.5M, FY22:-34196000 -34.2M, FY21:12725000 12.7M, FY20:-163628000 -163.6M, FY19:-34844000 -34.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:500000 0.5M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1000 -0.0M, Q2/2025:368000 0.4M, Q1/2025:-271036 -0.3M, Q3/2024:0 0.0M, Q2/2024:-257288 -0.3M

Quarterly Net worth Q3/2025:-7024000 -7.0M, Q2/2025:-14616000 -14.6M, Q1/2025:-12887000 -12.9M, Q3/2024:-15001000 -15.0M, Q2/2024:-12255000 -12.3M

Fund house & investment objective

Company Information Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Organisation Biotechnology

Employees 36

Industry Biotechnology

CEO Dr. Denise Vera Scots-Knight Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow